Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia

Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studie...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 17; no. 1; p. 76
Main Authors Peng, Hong-Xia, Liu, Xiao-Dan, Luo, Zi-Yan, Zhang, Xiao-Hong, Luo, Xue-Qun, Chen, Xiao, Jiang, Hua, Xu, Ling
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 25.01.2017
BioMed Central
Subjects
Acute lymphocytic leukemia
Analysis
Biomarkers, Tumor - genetics
Bone marrow
Cancer
Cell cycle
Child
Child health
Child, Preschool
Children & youth
Disease-Free Survival
Female
Gene expression
Gene Expression Regulation, Leukemic
Genetic aspects
Health aspects
Humans
Infant
Leukemia
Lymphoma
Male
Medical prognosis
Pathogenesis
Pediatrics
Polycomb Repressive Complex 1 - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Prognosis
Remission (Medicine)
Risk factors
Transcription Factors - genetics
Pediatric acute lymphoblastic leukemia
Sall4
Prognosis
Bmi-1
Online AccessGet full text

Cover

Abstract Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studied. The Bmi-1 expression levels in the bone marrow of 104 pediatric ALL patients and 18 normal control subjects were determined by using qRT-PCR. The association between the Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients was analyzed, and the correlation between Bmi-1 and the prognosis of pediatric ALL was calculated according to the Kaplan-Meier method. Furthermore, the association between Bmi-1 expression and its transcriptional regulator Sall4 was investigated. Compared to normal control subjects, patients with primary pediatric ALL exhibited upregulated levels of Bmi-1. However, these levels were sharply decreased in patients who achieved complete remission. A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Patients who overexpressed Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate (75.8%), whereas patients with lower Bmi-1 expression had an RFS of 94.1%. Furthermore, in ALL patients, the mRNA expression of Bmi-1 was positively correlated to the mRNA expression of Sall4a. Taken together, these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary ALL and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL.
AbstractList Background Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studied. Methods The Bmi-1 expression levels in the bone marrow of 104 pediatric ALL patients and 18 normal control subjects were determined by using qRT-PCR. The association between the Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients was analyzed, and the correlation between Bmi-1 and the prognosis of pediatric ALL was calculated according to the Kaplan-Meier method. Furthermore, the association between Bmi-1 expression and its transcriptional regulator Sall4 was investigated. Results Compared to normal control subjects, patients with primary pediatric ALL exhibited upregulated levels of Bmi-1. However, these levels were sharply decreased in patients who achieved complete remission. A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Patients who overexpressed Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate (75.8%), whereas patients with lower Bmi-1 expression had an RFS of 94.1%. Furthermore, in ALL patients, the mRNA expression of Bmi-1 was positively correlated to the mRNA expression of Sall4a. Conclusions Taken together, these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary ALL and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL. Keywords: Bmi-1, Pediatric acute lymphoblastic leukemia, Sall4, Prognosis
Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studied. The Bmi-1 expression levels in the bone marrow of 104 pediatric ALL patients and 18 normal control subjects were determined by using qRT-PCR. The association between the Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients was analyzed, and the correlation between Bmi-1 and the prognosis of pediatric ALL was calculated according to the Kaplan-Meier method. Furthermore, the association between Bmi-1 expression and its transcriptional regulator Sall4 was investigated. Compared to normal control subjects, patients with primary pediatric ALL exhibited upregulated levels of Bmi-1. However, these levels were sharply decreased in patients who achieved complete remission. A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Patients who overexpressed Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate (75.8%), whereas patients with lower Bmi-1 expression had an RFS of 94.1%. Furthermore, in ALL patients, the mRNA expression of Bmi-1 was positively correlated to the mRNA expression of Sall4a. Taken together, these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary ALL and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL.
BACKGROUNDBmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studied.METHODSThe Bmi-1 expression levels in the bone marrow of 104 pediatric ALL patients and 18 normal control subjects were determined by using qRT-PCR. The association between the Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients was analyzed, and the correlation between Bmi-1 and the prognosis of pediatric ALL was calculated according to the Kaplan-Meier method. Furthermore, the association between Bmi-1 expression and its transcriptional regulator Sall4 was investigated.RESULTSCompared to normal control subjects, patients with primary pediatric ALL exhibited upregulated levels of Bmi-1. However, these levels were sharply decreased in patients who achieved complete remission. A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Patients who overexpressed Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate (75.8%), whereas patients with lower Bmi-1 expression had an RFS of 94.1%. Furthermore, in ALL patients, the mRNA expression of Bmi-1 was positively correlated to the mRNA expression of Sall4a.CONCLUSIONSTaken together, these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary ALL and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL.
Background Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studied. Methods The Bmi-1 expression levels in the bone marrow of 104 pediatric ALL patients and 18 normal control subjects were determined by using qRT-PCR. The association between the Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients was analyzed, and the correlation between Bmi-1 and the prognosis of pediatric ALL was calculated according to the Kaplan-Meier method. Furthermore, the association between Bmi-1 expression and its transcriptional regulator Sall4 was investigated. Results Compared to normal control subjects, patients with primary pediatric ALL exhibited upregulated levels of Bmi-1. However, these levels were sharply decreased in patients who achieved complete remission. A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Patients who overexpressed Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate (75.8%), whereas patients with lower Bmi-1 expression had an RFS of 94.1%. Furthermore, in ALL patients, the mRNA expression of Bmi-1 was positively correlated to the mRNA expression of Sall4a. Conclusions Taken together, these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary ALL and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL.
Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various tumors; however, its expression related to the prognosis of pediatric patients with acute lymphoblastic leukemia (ALL) has not been well studied. The Bmi-1 expression levels in the bone marrow of 104 pediatric ALL patients and 18 normal control subjects were determined by using qRT-PCR. The association between the Bmi-1 expression and the clinicopathological characteristics of pediatric ALL patients was analyzed, and the correlation between Bmi-1 and the prognosis of pediatric ALL was calculated according to the Kaplan-Meier method. Furthermore, the association between Bmi-1 expression and its transcriptional regulator Sall4 was investigated. Compared to normal control subjects, patients with primary pediatric ALL exhibited upregulated levels of Bmi-1. However, these levels were sharply decreased in patients who achieved complete remission. A significant positive association between elevated Bmi-1 levels and a poor response to prednisone as well as an increased clinical risk was observed. Patients who overexpressed Bmi-1 at the time of diagnosis had a lower relapse-free survival (RFS) rate (75.8%), whereas patients with lower Bmi-1 expression had an RFS of 94.1%. Furthermore, in ALL patients, the mRNA expression of Bmi-1 was positively correlated to the mRNA expression of Sall4a. Taken together, these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary ALL and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL.
ArticleNumber 76
Audience Academic
Author Peng, Hong-Xia
Zhang, Xiao-Hong
Luo, Xue-Qun
Chen, Xiao
Xu, Ling
Liu, Xiao-Dan
Luo, Zi-Yan
Jiang, Hua
Author_xml – sequence: 1
  givenname: Hong-Xia
  surname: Peng
  fullname: Peng, Hong-Xia
– sequence: 2
  givenname: Xiao-Dan
  surname: Liu
  fullname: Liu, Xiao-Dan
– sequence: 3
  givenname: Zi-Yan
  surname: Luo
  fullname: Luo, Zi-Yan
– sequence: 4
  givenname: Xiao-Hong
  surname: Zhang
  fullname: Zhang, Xiao-Hong
– sequence: 5
  givenname: Xue-Qun
  surname: Luo
  fullname: Luo, Xue-Qun
– sequence: 6
  givenname: Xiao
  surname: Chen
  fullname: Chen, Xiao
– sequence: 7
  givenname: Hua
  surname: Jiang
  fullname: Jiang, Hua
– sequence: 8
  givenname: Ling
  surname: Xu
  fullname: Xu, Ling
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28122538$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFTEQhoNUbHv0B3gjC4LoxdYk-5W9EWrxo1AQ1F6HJDu7JzWbbJOs2H9v1lMPZ4tILhJmnnnDzLyn6Mg6Cwg9J_iMEFa_DYQyVuWYNHmByzYvHqETUjYkpyVujg7ex-g0hBucQIbZE3RMGaG0KtgJMteTh2E2ImpnM9dncQvZ5F10ubPKDWAhez_qnKQgdFrFkIlscs4v0GBd0CHTNptSTkSvVSbUHCEzd-O0ddKIEFPMwPwDRi2eose9MAGe3d8bdP3xw_eLz_nVl0-XF-dXuaqqNuaybouO9rUkDa4U7qUEVbBK0VLWtGpr1fZtTUlJFSglBVVSNqUqe9x2rBeyKDbo3U53muUInQIbvTB88noU_o47ofk6Y_WWD-4nr2hdFpQkgdf3At7dzhAiH3VQYIyw4ObA0_ApZRWpm4S-fIDeuNnb1N5CFYyVddLcU4MwwLXtXfpXLaL8vGS4xi1OTW_Q2T-odLo0PZV23-sUXxW8WRUkJsKvOIg5BH757euafXXAbkGYuA3OzMviwxp8cTi9_dj-miYBZAco70Lw0O8RgvliTL4zJk9-44sx-bKS5kGN0vGP6VKL2vyn8jcH-uZZ
CitedBy_id crossref_primary_10_1016_j_celrep_2018_12_030
crossref_primary_10_1002_ijc_31622
crossref_primary_10_1002_advs_202205573
crossref_primary_10_2147_CMAR_S240469
crossref_primary_10_3892_ijo_2017_4206
crossref_primary_10_1083_jcb_201808028
crossref_primary_10_1016_j_exphem_2022_02_004
crossref_primary_10_1186_s10020_024_00812_z
crossref_primary_10_1016_j_jds_2023_06_014
crossref_primary_10_1016_j_stem_2019_03_005
crossref_primary_10_3389_fonc_2019_01496
crossref_primary_10_1007_s12539_019_00325_y
crossref_primary_10_1177_15330338211070689
crossref_primary_10_1038_s41390_021_01854_3
crossref_primary_10_1016_j_htct_2020_01_002
crossref_primary_10_1155_2020_6980392
crossref_primary_10_3390_ijms221810107
Cites_doi 10.4236/scd.2012.22004
10.1016/0092-8674(91)90383-A
10.1016/0165-4608(88)90082-9
10.1038/leu.2010.325
10.1172/JCI200420800
10.1016/j.exphem.2014.01.005
10.1182/blood.V69.5.1289.1289
10.1016/S1470-2045(13)70452-2
10.1007/s10552-015-0654-9
10.1016/0092-8674(91)90382-9
10.1186/scrt199
10.1016/j.canlet.2003.07.009
10.1101/gad.415507
10.1038/modpathol.3800694
10.1007/s10549-008-9909-4
10.1158/0008-5472.CAN-06-0094
10.1038/nature02060
10.1182/blood-2006-02-001594
10.1016/S1470-2045(08)70229-8
10.1182/blood.V97.12.3896
10.1186/1475-2867-12-42
10.1038/cddis.2010.60
10.1186/1471-2407-10-133
10.1523/JNEUROSCI.1634-10.2010
10.1016/j.ccr.2007.08.032
10.1016/S0006-2952(02)01147-4
10.1007/s12013-014-0194-z
10.1111/j.1743-7563.2012.01564.x
10.1016/j.breast.2004.02.010
10.1007/s00268-012-1514-3
10.1182/blood-2008-04-148130
10.1136/jcp.2006.038752
10.1038/onc.2014.322
10.1054/bjoc.2001.1791
10.1016/j.eururo.2006.11.020
10.1016/S1470-2045(12)70580-6
10.1532/IJH97.05013
10.1038/nature01587
10.1073/pnas.0704001104
10.1186/1756-8722-6-73
10.1083/jcb.201003034
10.1056/NEJMra1400972
10.1523/JNEUROSCI.3452-04.2005
10.1186/1471-230X-12-146
10.1038/nature01572
10.1038/sj.leu.2404623
10.1038/leu.2011.65
10.1007/s13277-015-3525-9
10.1093/hmg/2.10.1597
ContentType Journal Article
Copyright COPYRIGHT 2017 BioMed Central Ltd.
Copyright BioMed Central 2017
The Author(s). 2017
Copyright_xml – notice: COPYRIGHT 2017 BioMed Central Ltd.
– notice: Copyright BioMed Central 2017
– notice: The Author(s). 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1186/s12885-017-3049-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


MEDLINE - Academic
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 76
ExternalDocumentID PMC5264321
4311842141
A480609069
28122538
10_1186_s12885_017_3049_3
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: No.81272310
– fundername: ;
  grantid: 2015A030313769
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c559t-b693d2f6b1705c0fbbec385c24b62596c9f962142ceccba2cbb74c4f09d8fab33
IEDL.DBID M48
ISSN 1471-2407
IngestDate Thu Aug 21 18:20:16 EDT 2025
Fri Jul 11 00:40:09 EDT 2025
Fri Jul 25 05:48:55 EDT 2025
Tue Jun 17 21:44:04 EDT 2025
Tue Jun 10 20:22:17 EDT 2025
Fri Jun 27 03:46:30 EDT 2025
Thu May 22 21:07:02 EDT 2025
Thu Apr 03 07:03:11 EDT 2025
Tue Jul 01 03:05:56 EDT 2025
Thu Apr 24 23:07:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Pediatric acute lymphoblastic leukemia
Sall4
Prognosis
Bmi-1
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c559t-b693d2f6b1705c0fbbec385c24b62596c9f962142ceccba2cbb74c4f09d8fab33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12885-017-3049-3
PMID 28122538
PQID 1863884664
PQPubID 44074
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5264321
proquest_miscellaneous_1862285167
proquest_journals_1863884664
gale_infotracmisc_A480609069
gale_infotracacademiconefile_A480609069
gale_incontextgauss_ISR_A480609069
gale_healthsolutions_A480609069
pubmed_primary_28122538
crossref_primary_10_1186_s12885_017_3049_3
crossref_citationtrail_10_1186_s12885_017_3049_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-01-25
PublicationDateYYYYMMDD 2017-01-25
PublicationDate_xml – month: 01
  year: 2017
  text: 2017-01-25
  day: 25
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC cancer
PublicationTitleAlternate BMC Cancer
PublicationYear 2017
Publisher BioMed Central Ltd
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
References W Cui (3049_CR53) 2006; 19
T Kajiume (3049_CR43) 2012; 02
JH Kim (3049_CR18) 2004; 13
A Honig (3049_CR19) 2010; 30
LB Song (3049_CR24) 2006; 66
NM Davies (3049_CR26) 2015; 26
M Chowdhury (3049_CR42) 2007; 21
J Lu (3049_CR51) 2011; 25
JC Ma (3049_CR49) 2013; 46
IH Ismail (3049_CR13) 2010; 191
A Amsterdam (3049_CR46) 2002; 64
FJ Kemenade van (3049_CR22) 2001; 97
AS Yong (3049_CR27) 2011; 25
F Wang (3049_CR48) 2013; 6
IK Park (3049_CR11) 2003; 423
S Ueno (3049_CR52) 2014; 42
J Lessard (3049_CR9) 2003; 423
S Bea (3049_CR21) 2001; 61
GF Yang (3049_CR35) 2010; 10
SP Hunger (3049_CR1) 2015; 373
SW Bruggeman (3049_CR14) 2007; 12
JH Kim (3049_CR20) 2004; 203
MJ Alkema (3049_CR7) 1993; 2
AV Molofsky (3049_CR10) 2003; 425
D Yu (3049_CR39) 2015; 71
AE Yeoh (3049_CR33) 2013; 14
B Choy (3049_CR41) 2012; 12
Q Shen (3049_CR31) 2012; 12
S Vonlanthen (3049_CR17) 2001; 84
Y Ma (3049_CR50) 2006; 108
S Chen (3049_CR32) 2013; 4
YJ Choi (3049_CR37) 2009; 113
T DiMauro (3049_CR16) 2015; 34
J Yang (3049_CR30) 2007; 104
R Berger (3049_CR6) 1988; 36
Y Haupt (3049_CR4) 1991; 65
M Mohty (3049_CR28) 2008; 112
AP Bracken (3049_CR45) 2007; 21
S Facchino (3049_CR12) 2010; 30
GJ Leenders van (3049_CR25) 2007; 52
JC Galen van (3049_CR29) 2007; 60
D Zencak (3049_CR15) 2005; 25
YQ Tong (3049_CR40) 2012; 8
R Bose (3049_CR47) 2010; 1
Q Long (3049_CR38) 2015; 36
IK Park (3049_CR44) 2004; 113
LC Bailey (3049_CR2) 2008; 9
CH Pui (3049_CR8) 1987; 69
Y Wang (3049_CR36) 2012; 36
M Lohuizen van (3049_CR5) 1991; 65
D Bhojwani (3049_CR3) 2013; 14
M Sawa (3049_CR23) 2005; 82
JM Remes Troche (3049_CR34) 2011; 76
26387087 - Cancer Causes Control. 2015 Nov;26(11):1603-16
23201546 - Clin Biochem. 2013 Mar;46(4-5):304-7
25263442 - Oncogene. 2015 Jul 23;34(30):4011-7
17557835 - Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10494-9
20592341 - Anticancer Res. 2010 May;30(5):1559-64
21468036 - Leukemia. 2011 Jul;25(7):1211-3
24176570 - Lancet Oncol. 2013 Nov;14(12):e508-23
3060249 - Cancer Genet Cytogenet. 1988 Nov;36(1):123-30
23078618 - BMC Gastroenterol. 2012 Oct 18;12 :146
24463278 - Exp Hematol. 2014 Apr;42(4):307-316.e8
24283704 - J Hematol Oncol. 2013 Sep 26;6(1):73
18565849 - Blood. 2008 Sep 1;112(5):2163-6
11355949 - Br J Cancer. 2001 May 18;84(10 ):1372-6
22898137 - Asia Pac J Clin Oncol. 2012 Dec;8(4):e55-62
11289106 - Cancer Res. 2001 Mar 15;61(6):2409-12
25241082 - Cell Biochem Biophys. 2015 Jan;71(1):261-9
17344414 - Genes Dev. 2007 Mar 1;21(5):525-30
16998462 - Mod Pathol. 2006 Dec;19(12):1585-92
16837630 - J Clin Pathol. 2007 Feb;60(2):167-72
23639321 - Lancet Oncol. 2013 May;14(6):e205-17
25967455 - Tumour Biol. 2015 Sep;36(10 ):8007-14
8268912 - Hum Mol Genet. 1993 Oct;2(10 ):1597-603
23632167 - Stem Cell Res Ther. 2013 Apr 30;4(2):49
18760243 - Lancet Oncol. 2008 Sep;9(9):873-83
16105758 - Int J Hematol. 2005 Jul;82(1):42-7
20668194 - J Neurosci. 2010 Jul 28;30(30):10096-111
14574365 - Nature. 2003 Oct 30;425(6961):962-7
14732230 - Cancer Lett. 2004 Jan 20;203(2):217-24
16763212 - Blood. 2006 Oct 15;108(8):2726-35
21724491 - Rev Gastroenterol Mex. 2011 Apr-Jun;76(2):155-68
14722607 - J Clin Invest. 2004 Jan;113(2):175-9
22366984 - World J Surg. 2012 May;36(5):1189-94
26465987 - N Engl J Med. 2015 Oct 15;373(16):1541-52
15958744 - J Neurosci. 2005 Jun 15;25(24):5774-83
18228133 - Breast Cancer Res Treat. 2009 Jan;113(1):83-93
11389032 - Blood. 2001 Jun 15;97(12 ):3896-901
12714970 - Nature. 2003 May 15;423(6937):255-60
20377880 - BMC Cancer. 2010 Apr 08;10 :133
1904008 - Cell. 1991 May 31;65(5):737-52
17377594 - Leukemia. 2007 May;21(5):1116-22
1904009 - Cell. 1991 May 31;65(5):753-63
23067006 - Cancer Cell Int. 2012 Oct 15;12(1):42
21368868 - Cell Death Dis. 2010 Nov 04;1:e92
16778197 - Cancer Res. 2006 Jun 15;66(12 ):6225-32
12213578 - Biochem Pharmacol. 2002 Sep;64(5-6):843-50
17134822 - Eur Urol. 2007 Aug;52(2):455-63
17936558 - Cancer Cell. 2007 Oct;12 (4):328-41
15454193 - Breast. 2004 Oct;13(5):383-8
2952182 - Blood. 1987 May;69(5):1289-93
20921134 - J Cell Biol. 2010 Oct 4;191(1):45-60
21252986 - Leukemia. 2011 Apr;25(4):629-37
12714971 - Nature. 2003 May 15;423(6937):302-5
References_xml – volume: 02
  start-page: 25
  issue: 02
  year: 2012
  ident: 3049_CR43
  publication-title: Stem Cell Discovery
  doi: 10.4236/scd.2012.22004
– volume: 65
  start-page: 753
  issue: 5
  year: 1991
  ident: 3049_CR4
  publication-title: Cell
  doi: 10.1016/0092-8674(91)90383-A
– volume: 36
  start-page: 123
  issue: 1
  year: 1988
  ident: 3049_CR6
  publication-title: Cancer Genet Cytogenet
  doi: 10.1016/0165-4608(88)90082-9
– volume: 25
  start-page: 629
  issue: 4
  year: 2011
  ident: 3049_CR27
  publication-title: Leukemia
  doi: 10.1038/leu.2010.325
– volume: 113
  start-page: 175
  issue: 2
  year: 2004
  ident: 3049_CR44
  publication-title: J Clin Invest
  doi: 10.1172/JCI200420800
– volume: 42
  start-page: 307
  issue: 4
  year: 2014
  ident: 3049_CR52
  publication-title: Exp Hematol
  doi: 10.1016/j.exphem.2014.01.005
– volume: 69
  start-page: 1289
  issue: 5
  year: 1987
  ident: 3049_CR8
  publication-title: Blood
  doi: 10.1182/blood.V69.5.1289.1289
– volume: 14
  start-page: e508
  issue: 12
  year: 2013
  ident: 3049_CR33
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70452-2
– volume: 26
  start-page: 1603
  issue: 11
  year: 2015
  ident: 3049_CR26
  publication-title: Cancer Causes Control
  doi: 10.1007/s10552-015-0654-9
– volume: 65
  start-page: 737
  issue: 5
  year: 1991
  ident: 3049_CR5
  publication-title: Cell
  doi: 10.1016/0092-8674(91)90382-9
– volume: 4
  start-page: 49
  issue: 2
  year: 2013
  ident: 3049_CR32
  publication-title: Stem Cell Res Ther
  doi: 10.1186/scrt199
– volume: 203
  start-page: 217
  issue: 2
  year: 2004
  ident: 3049_CR20
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2003.07.009
– volume: 21
  start-page: 525
  issue: 5
  year: 2007
  ident: 3049_CR45
  publication-title: Genes Dev
  doi: 10.1101/gad.415507
– volume: 19
  start-page: 1585
  issue: 12
  year: 2006
  ident: 3049_CR53
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.3800694
– volume: 113
  start-page: 83
  issue: 1
  year: 2009
  ident: 3049_CR37
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-008-9909-4
– volume: 76
  start-page: 155
  issue: 2
  year: 2011
  ident: 3049_CR34
  publication-title: Rev Gastroenterol Mex
– volume: 66
  start-page: 6225
  issue: 12
  year: 2006
  ident: 3049_CR24
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-0094
– volume: 425
  start-page: 962
  issue: 6961
  year: 2003
  ident: 3049_CR10
  publication-title: Nature
  doi: 10.1038/nature02060
– volume: 108
  start-page: 2726
  issue: 8
  year: 2006
  ident: 3049_CR50
  publication-title: Blood
  doi: 10.1182/blood-2006-02-001594
– volume: 9
  start-page: 873
  issue: 9
  year: 2008
  ident: 3049_CR2
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(08)70229-8
– volume: 97
  start-page: 3896
  issue: 12
  year: 2001
  ident: 3049_CR22
  publication-title: Blood
  doi: 10.1182/blood.V97.12.3896
– volume: 12
  start-page: 42
  issue: 1
  year: 2012
  ident: 3049_CR31
  publication-title: Cancer Cell Int
  doi: 10.1186/1475-2867-12-42
– volume: 1
  start-page: e92
  year: 2010
  ident: 3049_CR47
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2010.60
– volume: 10
  start-page: 133
  year: 2010
  ident: 3049_CR35
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-10-133
– volume: 30
  start-page: 10096
  issue: 30
  year: 2010
  ident: 3049_CR12
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.1634-10.2010
– volume: 12
  start-page: 328
  issue: 4
  year: 2007
  ident: 3049_CR14
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2007.08.032
– volume: 64
  start-page: 843
  issue: 5–6
  year: 2002
  ident: 3049_CR46
  publication-title: Biochem Pharmacol
  doi: 10.1016/S0006-2952(02)01147-4
– volume: 71
  start-page: 261
  issue: 1
  year: 2015
  ident: 3049_CR39
  publication-title: Cell Biochem Biophys
  doi: 10.1007/s12013-014-0194-z
– volume: 30
  start-page: 1559
  issue: 5
  year: 2010
  ident: 3049_CR19
  publication-title: Anticancer Res
– volume: 8
  start-page: e55
  issue: 4
  year: 2012
  ident: 3049_CR40
  publication-title: Asia Pac J Clin Oncol
  doi: 10.1111/j.1743-7563.2012.01564.x
– volume: 13
  start-page: 383
  issue: 5
  year: 2004
  ident: 3049_CR18
  publication-title: Breast
  doi: 10.1016/j.breast.2004.02.010
– volume: 36
  start-page: 1189
  issue: 5
  year: 2012
  ident: 3049_CR36
  publication-title: World J Surg
  doi: 10.1007/s00268-012-1514-3
– volume: 112
  start-page: 2163
  issue: 5
  year: 2008
  ident: 3049_CR28
  publication-title: Blood
  doi: 10.1182/blood-2008-04-148130
– volume: 60
  start-page: 167
  issue: 2
  year: 2007
  ident: 3049_CR29
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2006.038752
– volume: 34
  start-page: 4011
  issue: 30
  year: 2015
  ident: 3049_CR16
  publication-title: Oncogene
  doi: 10.1038/onc.2014.322
– volume: 84
  start-page: 1372
  issue: 10
  year: 2001
  ident: 3049_CR17
  publication-title: Br J Cancer
  doi: 10.1054/bjoc.2001.1791
– volume: 52
  start-page: 455
  issue: 2
  year: 2007
  ident: 3049_CR25
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2006.11.020
– volume: 14
  start-page: e205
  issue: 6
  year: 2013
  ident: 3049_CR3
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70580-6
– volume: 82
  start-page: 42
  issue: 1
  year: 2005
  ident: 3049_CR23
  publication-title: Int J Hematol
  doi: 10.1532/IJH97.05013
– volume: 423
  start-page: 302
  issue: 6937
  year: 2003
  ident: 3049_CR11
  publication-title: Nature
  doi: 10.1038/nature01587
– volume: 104
  start-page: 10494
  issue: 25
  year: 2007
  ident: 3049_CR30
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0704001104
– volume: 6
  start-page: 73
  issue: 1
  year: 2013
  ident: 3049_CR48
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-6-73
– volume: 191
  start-page: 45
  issue: 1
  year: 2010
  ident: 3049_CR13
  publication-title: J Cell Biol
  doi: 10.1083/jcb.201003034
– volume: 373
  start-page: 1541
  issue: 16
  year: 2015
  ident: 3049_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1400972
– volume: 46
  start-page: 304
  issue: 4–5
  year: 2013
  ident: 3049_CR49
  publication-title: Clin Biochem
– volume: 25
  start-page: 5774
  issue: 24
  year: 2005
  ident: 3049_CR15
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.3452-04.2005
– volume: 12
  start-page: 146
  year: 2012
  ident: 3049_CR41
  publication-title: BMC Gastroenterol
  doi: 10.1186/1471-230X-12-146
– volume: 423
  start-page: 255
  issue: 6937
  year: 2003
  ident: 3049_CR9
  publication-title: Nature
  doi: 10.1038/nature01572
– volume: 21
  start-page: 1116
  issue: 5
  year: 2007
  ident: 3049_CR42
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404623
– volume: 25
  start-page: 1211
  issue: 7
  year: 2011
  ident: 3049_CR51
  publication-title: Leukemia
  doi: 10.1038/leu.2011.65
– volume: 61
  start-page: 2409
  issue: 6
  year: 2001
  ident: 3049_CR21
  publication-title: Cancer Res
– volume: 36
  start-page: 8007
  issue: 10
  year: 2015
  ident: 3049_CR38
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3525-9
– volume: 2
  start-page: 1597
  issue: 10
  year: 1993
  ident: 3049_CR7
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/2.10.1597
– reference: 24463278 - Exp Hematol. 2014 Apr;42(4):307-316.e8
– reference: 11355949 - Br J Cancer. 2001 May 18;84(10 ):1372-6
– reference: 21724491 - Rev Gastroenterol Mex. 2011 Apr-Jun;76(2):155-68
– reference: 18228133 - Breast Cancer Res Treat. 2009 Jan;113(1):83-93
– reference: 11389032 - Blood. 2001 Jun 15;97(12 ):3896-901
– reference: 17557835 - Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10494-9
– reference: 16998462 - Mod Pathol. 2006 Dec;19(12):1585-92
– reference: 2952182 - Blood. 1987 May;69(5):1289-93
– reference: 26387087 - Cancer Causes Control. 2015 Nov;26(11):1603-16
– reference: 24283704 - J Hematol Oncol. 2013 Sep 26;6(1):73
– reference: 23639321 - Lancet Oncol. 2013 May;14(6):e205-17
– reference: 14574365 - Nature. 2003 Oct 30;425(6961):962-7
– reference: 11289106 - Cancer Res. 2001 Mar 15;61(6):2409-12
– reference: 8268912 - Hum Mol Genet. 1993 Oct;2(10 ):1597-603
– reference: 15454193 - Breast. 2004 Oct;13(5):383-8
– reference: 20377880 - BMC Cancer. 2010 Apr 08;10 :133
– reference: 12714971 - Nature. 2003 May 15;423(6937):302-5
– reference: 24176570 - Lancet Oncol. 2013 Nov;14(12):e508-23
– reference: 1904008 - Cell. 1991 May 31;65(5):737-52
– reference: 14732230 - Cancer Lett. 2004 Jan 20;203(2):217-24
– reference: 16763212 - Blood. 2006 Oct 15;108(8):2726-35
– reference: 15958744 - J Neurosci. 2005 Jun 15;25(24):5774-83
– reference: 18760243 - Lancet Oncol. 2008 Sep;9(9):873-83
– reference: 26465987 - N Engl J Med. 2015 Oct 15;373(16):1541-52
– reference: 25241082 - Cell Biochem Biophys. 2015 Jan;71(1):261-9
– reference: 17936558 - Cancer Cell. 2007 Oct;12 (4):328-41
– reference: 25263442 - Oncogene. 2015 Jul 23;34(30):4011-7
– reference: 21252986 - Leukemia. 2011 Apr;25(4):629-37
– reference: 23632167 - Stem Cell Res Ther. 2013 Apr 30;4(2):49
– reference: 20592341 - Anticancer Res. 2010 May;30(5):1559-64
– reference: 17134822 - Eur Urol. 2007 Aug;52(2):455-63
– reference: 21468036 - Leukemia. 2011 Jul;25(7):1211-3
– reference: 22898137 - Asia Pac J Clin Oncol. 2012 Dec;8(4):e55-62
– reference: 17377594 - Leukemia. 2007 May;21(5):1116-22
– reference: 16837630 - J Clin Pathol. 2007 Feb;60(2):167-72
– reference: 23067006 - Cancer Cell Int. 2012 Oct 15;12(1):42
– reference: 3060249 - Cancer Genet Cytogenet. 1988 Nov;36(1):123-30
– reference: 21368868 - Cell Death Dis. 2010 Nov 04;1:e92
– reference: 16778197 - Cancer Res. 2006 Jun 15;66(12 ):6225-32
– reference: 22366984 - World J Surg. 2012 May;36(5):1189-94
– reference: 12714970 - Nature. 2003 May 15;423(6937):255-60
– reference: 12213578 - Biochem Pharmacol. 2002 Sep;64(5-6):843-50
– reference: 14722607 - J Clin Invest. 2004 Jan;113(2):175-9
– reference: 16105758 - Int J Hematol. 2005 Jul;82(1):42-7
– reference: 20668194 - J Neurosci. 2010 Jul 28;30(30):10096-111
– reference: 1904009 - Cell. 1991 May 31;65(5):753-63
– reference: 25967455 - Tumour Biol. 2015 Sep;36(10 ):8007-14
– reference: 18565849 - Blood. 2008 Sep 1;112(5):2163-6
– reference: 17344414 - Genes Dev. 2007 Mar 1;21(5):525-30
– reference: 20921134 - J Cell Biol. 2010 Oct 4;191(1):45-60
– reference: 23201546 - Clin Biochem. 2013 Mar;46(4-5):304-7
– reference: 23078618 - BMC Gastroenterol. 2012 Oct 18;12 :146
SSID ssj0017808
Score 2.2973967
Snippet Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in various...
Background Bmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in...
BACKGROUNDBmi-1, the B cell-specific moloney murine leukemia virus insertion site 1, is a member of the Polycomb-group (PcG) family and acts as an oncogene in...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 76
SubjectTerms Acute lymphocytic leukemia
Analysis
Biomarkers, Tumor - genetics
Bone marrow
Cancer
Cell cycle
Child
Child health
Child, Preschool
Children & youth
Disease-Free Survival
Female
Gene expression
Gene Expression Regulation, Leukemic
Genetic aspects
Health aspects
Humans
Infant
Leukemia
Lymphoma
Male
Medical prognosis
Pathogenesis
Pediatrics
Polycomb Repressive Complex 1 - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Prognosis
Remission (Medicine)
Risk factors
Transcription Factors - genetics
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4s2WAgYhISFZTRzHcU6oIKqCVA7ASnuzbK8NEdt42ewe-u-ZSbyh4dBr_I3ymBnP2J58Q8gb431RlF6yKpM1EzbUzArnmIdw4U0QfBlwH_L8qzybiy-LcpE23LpUVrmfE_uJehkd7pEf5wosRSEZ-vv1H4Zdo_B0NbXQuEluIXUZlnRVi3HBlVcqU-kkE8SPO5iLFZaqgVtBYsyKSSz6f0a-EpKm5ZJX4s_pPXI3JY70ZND0fXLDtw_I7fN0NP6QrObrzdBXHr40jYFCZkeRhSGy2LoIduLph4uG5XARhbYdNXQd4wZBWG3XdLRp6XrfuoMat9t6uroEdUcLOTbcl6787re_aMwjMj_99OPjGUutFJiDJcOWWVkXSx6kRfYclwULqitU6biwuACSrg61RPY1Byq1hjtrK-FEyOqlCsYWxWNy0MbWPyVU5taXspZLVQZRi8w4rqRS1pTCF7krZiTbf1TtEs84trtY6X69oaQe9KBBDxr1oEHk3SiyHkg2rgO_RE3p4T_R0UH1iVCZzGowuRl53SOQ3qLF-pmfZtd1-vP3bxPQ2wQKER7PmfQ7ArwkMmJNkEcTJPifmw7vTUYn_-_0P2udkVfjMEpiTVvr467HcA4Jr6xm5MlgYePbc8i7OMSiGakmtjcCkBV8OtI2v3p28BJS3ILnh9c_1jNyh6MjZDnj5RE52G52_jmkV1v7ovehv_IvJUY
  priority: 102
  providerName: ProQuest
Title Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia
URI https://www.ncbi.nlm.nih.gov/pubmed/28122538
https://www.proquest.com/docview/1863884664
https://www.proquest.com/docview/1862285167
https://pubmed.ncbi.nlm.nih.gov/PMC5264321
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dixMxEA_3AeKL-G31rFEEQYi3zWaz2QeRq9xxCj2kWii-hCRNtNjbrd0WvP_emf2oXTl88GUfNjPsx_xmZ7KZ_IaQl8b7OE68ZGkkMyZsyJgVzjEP4cKbIPgs4H_I0YU8n4iP02S6R9r2Vs0LLK-d2mE_qclq8ebXz6t34PBvK4dX8riEb6zCEjRwF0h4WbxPDiEwpeinI_FnUSFVkWoWNq9VQ2JgiHc8wc0qO1Hq72_1TrDqFlLuRKaz2-RWk1LSkxoDd8iez--SG6Nm0fweWUyWq7rjPNiAFoFCzkeRn6FgRe4KQJCnw8s5G8BJVFqX1NBlUaxQCOvw5iWd53TZNvWgxm3Wni6uAAiFhewbrksXfvPDX87NfTI5O_3y_pw1TRaYg8nEmlmZxTMepEVeHRcFC0aNVeK4sDg1ki4LmUReNgfGtoY7a1PhRIiymQrGxvEDcpAXuX9EqBxYn8hMzlQSRCYi47iSSlmTCB8PXNwjUftStWsYyLERxkJXMxEldW0SDSbRaBINKq-3KsuafuNfws_QUrreQbp1XX0iVCSjDMDYIy8qCSS-yLGy5pvZlKX-8HncEXrVCIUCbs-ZZqMCPCRyZXUkjzqS4JmuO9xCRrfA1nDnsVJI6t8jz7fDqInVbrkvNpUM55AKy7RHHtYI2z59i9AeSTvY2wogX3h3JJ9_r3jDE0h-Yz54_N-aT8hNju4SDRhPjsjBerXxTyEnW9s-2U-naZ8cDk8vPo371Z-NfuV9cBwPv_4GS4E59w
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgJeEHc6BjMIhIRkLXEc13lAaINNLVsrNFZpb57tOlCtS0rTCu1P8Rs5p7mw8LC3vcbHiu1ztX38HULeGu-jKPaS9QKZMGHThFnhHPPgLrxJBZ-keA45HMn-WHw9i882yJ_6LQymVdY2cW2oJ7nDM_LdUIGkKARD_zT_xbBqFN6u1iU0SrE48le_YctWfBx8Af6-4_zw4PRzn1VVBZiD6HnJrEyiCU-lRSAZF6QWZhGp2HFhcS8gXZImEoHIHMzOGu6s7Qkn0iCZqNRYPAAFk78pItjKdMjm_sHo20lzb9FTgaruTmHAuwVYf4XJcaDIEIqzqOX9_vcB15xgO0Hzmsc7fEDuV6Eq3Stl6yHZ8NkjcmdYXcY_JrPxfFFWsgfe0jylEEtSxH3IWZ65HCTT0_3LKQvhI3ZaFtTQeZ4vkAjz-6YFnWZ0XhcLocatlp7OrkDAcgtRPfyXzvzqwl9OzRMyvpVlfko6WZ7554TK0PpYJnKi4lQkIjCOK6mUNbHwUeiiLgnqRdWuQjbHAhszvd7hKKlLPmjgg0Y-aOjyoekyL2E9biLeQU7p8mVqYxL0nlCBDBIQ8i55s6ZAQI0MM3Z-mFVR6MH3kxbR-4oozWF4zlQPIGCSiMHVotxuUYLGu3ZzLTK6sjiF_qcfXfK6acaemEWX-Xy1puEcQmzZ65JnpYQ1s-cQ6XHwfl3Sa8leQ4A45O2WbPpzjUceQ1Ad8XDr5mHtkLv90-GxPh6Mjl6QexyVIggZj7dJZ7lY-ZcQ3C3tq0qjKDm_bSX-C-wcZSs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Upregulation+of+the+proto-oncogene+Bmi-1+predicts+a+poor+prognosis+in+pediatric+acute+lymphoblastic+leukemia&rft.jtitle=BMC+cancer&rft.au=Peng%2C+Hong-Xia&rft.au=Liu%2C+Xiao-Dan&rft.au=Luo%2C+Zi-Yan&rft.au=Zhang%2C+Xiao-Hong&rft.date=2017-01-25&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=17&rft_id=info:doi/10.1186%2Fs12885-017-3049-3&rft_id=info%3Apmid%2F28122538&rft.externalDocID=PMC5264321
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon